Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study

CIBERESUCICOVID Project (COV20/00110, ISCIII)

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageAmerican English
Pages (from-to)256-308
Number of pages53
JournalJournal of Infection
Volume86
Issue number3
DOIs
StateIndexed - Mar 2023

Bibliographical note

Funding Information:
This study was supported by the Instituto de Salud Carlos III de Madrid ( COV20/00110 , ISCIII); Fondo Europeo de Desarrollo Regional (FEDER); "Una manera de hacer Europa"; and Centro de Investigación Biomédica En Red – Enfermedades Respiratorias (CIBERES). DdGC has received financial support from the Instituto de Salud Carlos III (Miguel Servet 2020: CP20/00041 ), co-funded by European Social Fund (ESF) / “Investing in your future”. CC received a grant from the Fondo de Investigación Sanitaria ( PI19/00207 ), Instituto de Salud Carlos III, co-funded by the European Union.

Keywords

  • COVID-19
  • Critically ill patients
  • Intensive care
  • Outcomes
  • Remdesivir

Cite this